Modality
Gene Therapy
MOA
BETi
Target
CD3
Pathway
Ferroptosis
PsoriasisObesity
Development Pipeline
Preclinical
~May 2011
→ ~Aug 2012
Phase 1
~Nov 2012
→ ~Feb 2014
Phase 2
~May 2014
→ ~Aug 2015
Phase 3
~Nov 2015
→ ~Feb 2017
NDA/BLA
~May 2017
→ ~Aug 2018
Approved
Nov 2018
→ Aug 2028
ApprovedCurrent
NCT08476221
2,727 pts·Obesity
2020-02→2028-08·Completed
NCT03861025
2,421 pts·Obesity
2021-12→TBD·Recruiting
NCT07684923
269 pts·Psoriasis
2018-11→2026-10·Not yet recruiting
5,417 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2026-10-227mo awayPh3 Readout· Psoriasis
2028-08-212.4y awayPh3 Readout· Obesity
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Not yet…
Approved
Complet…
Approved
Recruit…
Catalysts
Ph3 Readout
2026-10-22 · 7mo away
Psoriasis
Ph3 Readout
2028-08-21 · 2.4y away
Obesity
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08476221 | Approved | Obesity | Completed | 2727 | PFS |
| NCT03861025 | Approved | Obesity | Recruiting | 2421 | Mayo |
| NCT07684923 | Approved | Psoriasis | Not yet recr... | 269 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-8021 | Hansoh Pharma | Approved | BTK |